Hematology

Latest News

$The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com$

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

By Jared Kaltwasser

May 23rd 2025

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

Even among patients with MDS and anemia with a high transfusion burden, 7 of 12 patients who responded experienced responses lasting longer than 6 months. | Image Credit: Eleni - stock.adobe.com

Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

By Rose McNulty

May 22nd 2025

Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

By AJMC Contributor

May 17th 2025

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

By AJMC Contributor

May 16th 2025

$Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com$

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

By Courtney Flaherty

May 16th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

More News

Vorinostat Added to Standard Chemotherapy Reduced the Incidence of Acute GVHD

December 10th 2012

Vorinostat Added to Standard Chemotherapy Reduced the Incidence of Acute GVHD

Vorinostat added to standard chemotherapy before, during, and after hematopoietic stem cell transplantation reduced the cumulative incidence of graft-versus-host disease in a phase I/II trial reported at the 54th Annual Meeting of the American Society of Hematology.

Encouraging Phase II Data for All-Oral First-Line Regimen in Newly Diagnosed Multiple Myeloma

December 9th 2012

Encouraging Phase II Data for All-Oral First-Line Regimen in Newly Diagnosed Multiple Myeloma

An investigational, weekly, oral proteosome inhibitor called MLN9708 achieved excellent response rates when combined with lenalidomide and dexamethasone as up-front treatment of newly diagnosed patients with multiple myeloma, according to results of a phase II trial presented at the 54th Annual Meeting of the American Society of Hematology.

Preliminary Evidence Suggests Ibrutinib Is a Home-Run for CLL

December 9th 2012

Preliminary Evidence Suggests Ibrutinib Is a Home-Run for CLL

Ibrutinib, an investigational Bruton's tyrosine kinase inhibitor, achieved excellent results in clinical trials of patients with chronic lymphocytic leukemia (CLL) presented at the 54th Annual Meeting of the American Society of Hematology.

Extending Anticoagulation With Apixaban Reduces Recurrent VTE

December 9th 2012

Extending Anticoagulation With Apixaban Reduces Recurrent VTE

Extended anticoagulation with fixed doses of the oral Factor Xa inhibitor apixaban significantly reduced the incidence of symptomatic recurrent venous thromboembolism (VTE) or death without increasing the risk of major bleeding in patients with VTE who had already completed up to 12 months of anticoagulation.

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions